NLS Pharmaceutics AG
NASDAQ:NLSP
NLS Pharmaceutics AG
NASDAQ:NLSP
Price:
0.762
USD
2.97%
Market Closed
Market Cap:
$4.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Lattice Semiconductor Corp
NASDAQ:LSCC
|
US |
NLS Pharmaceutics AG
Note Receivable
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
NLS Pharmaceutics AG
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oculis Holding AG
NASDAQ:OCS
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Note Receivable
$33m
|
CAGR 3-Years
22%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
NLS Pharmaceutics AG
Glance View
NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder. The company is headquartered in Stans, Nidwalden and currently employs 6 full-time employees. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
NLSP
Intrinsic Value
0.278
USD
Overvaluation 64%
